OverviewSuggest Edit

Psychemedics Corporation provides testing services for the detection of drug abuse through the analysis of hair samples. The Company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. Psychemedics offers its services to employers for applicant and employee testing, treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use.

TypePublic
Founded1985
HQActon, US
Websitepsychemedics.com
Employee Ratings2.4

Latest Updates

Employees (est.) (Dec 2018)250(+9%)
Revenue (FY, 2018)$42.7 M(+8%)
Share Price (Oct 2019)$9.4 (+2%)

Key People/Management at Psychemedics

Raymond C. Kubacki

Raymond C. Kubacki

Chairman, President and C.E.O.
Neil Lerner

Neil Lerner

Vice President - Finance
Michael I. Schaffer

Michael I. Schaffer

Vice President-Laboratory Operations
Show more

Psychemedics Office Locations

Psychemedics has an office in Acton
Acton, US (HQ)
125 Nagog Park #200
Show all (1)

Psychemedics Financials and Metrics

Psychemedics Revenue

Psychemedics's revenue was reported to be $42.67 m in FY, 2018
USD

Revenue (Q2, 2019)

9.3m

Gross profit (Q2, 2019)

4.2m

Gross profit margin (Q2, 2019), %

44.9%

Net income (Q2, 2019)

768.0k

EBIT (Q2, 2019)

1.3m

Market capitalization (16-Oct-2019)

52.4m

Closing stock price (16-Oct-2019)

9.4

Cash (30-Jun-2019)

7.1m

EV

46.7m
Psychemedics's current market capitalization is $52.4 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

26.9m29.2m27.0m39.0m39.7m42.7m

Revenue growth, %

9%(8%)45%

Cost of goods sold

11.5m14.3m17.5m19.9m22.1m

Gross profit

15.4m12.7m21.5m19.8m20.6m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

7.1m7.0m7.7m7.7m7.0m7.1m6.7m9.7m11.8m10.2m9.7m10.0m10.9m10.8m11.0m9.8m9.3m

Cost of goods sold

2.9m3.2m3.8m3.7m3.7m3.6m3.9m4.5m4.7m4.9m5.1m4.9m5.6m5.6m5.7m5.4m5.1m

Gross profit

4.2m3.8m3.9m4.0m3.3m3.5m2.7m5.2m7.1m5.3m4.6m5.1m5.4m5.2m5.4m4.4m4.2m

Gross profit Margin, %

59%54%51%52%47%49%41%54%60%52%48%51%49%48%49%45%45%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

4.0m3.6m2.7m3.9m8.2m4.1m

Accounts Receivable

4.4m4.1m3.5m5.8m

Inventories

769.3k690.0k1.1m1.1m

Current Assets

10.0m10.6m8.5m10.9m13.9m13.9m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

3.8m3.2m1.5m6.7m6.1m4.6m

Depreciation and Amortization

872.2k1.1m1.7m2.3m2.8m3.1m

Accounts Payable

(159.2k)334.5k(97.8k)144.0k(990.0k)77.0k

Cash From Operating Activities

6.0m4.5m4.6m9.3m9.1m7.9m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

1.6m2.7m2.4m3.8m1.3m2.4m3.7m627.0k1.4m

Depreciation and Amortization

1.4m2.1m753.0k1.5m2.3m764.0k1.5m

Accounts Payable

577.1k778.5k1.2m683.2k475.0k589.6k635.4k1.3m988.5k1.1m622.0k(976.0k)(263.0k)(116.0k)322.0k394.0k(306.0k)(428.0k)

Cash From Operating Activities

3.4m7.1m1.4m3.6m4.0m368.0k1.7m
USDY, 2019

EV/EBIT

35.2 x

EV/CFO

27.6 x

Financial Leverage

1.4 x
Show all financial metrics

Psychemedics Online and Social Media Presence

Embed Graph

Psychemedics News and Updates

Psychemedics Corporation Announces New Brazilian Distribution Agreement

ACTON, Mass., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (Nasdaq:PMD) announced today that it has entered into a new distribution agreement in Brazil with Sansão Holding S.A. and with Toxicologia Pardini Ltda., our existing independent distributor in Brazil, formerly known as Psyc…

Psychemedics Announces Second Quarter Results and Declares 92nd Consecutive Quarterly Dividend

ACTON, Mass., July 23, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced second quarter financial results for the period ended June 30, 2019.  The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of August 6, 2019, to …

Psychemedics Announces First Quarter Results and Declares 91st Consecutive Quarterly Dividend

ACTON, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced first quarter financial results for the period ended March 31, 2019.  The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of May 7, 2019, to be…

New Psychemedics Offering Further Enhances Cocaine Detection

Industry’s first commercial application of hydroxycocaines for detection Industry’s first commercial application of hydroxycocaines for detection

Psychemedics Corporation Announces 3rd Straight Year of Record Revenue; Declares 90th Consecutive Quarterly Dividend

ACTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) today announced fourth quarter and year-end financial results for the period ended December 31, 2018. The Company also announced a quarterly dividend of $0.18 per share payable to shareholders of record as of Ma…

Psychemedics Announces Quarterly Results

Declares 89th Consecutive Quarterly Dividend

Psychemedics Blogs

More Education Required before we call CBD a Cure-all

I read a column in my local paper serving a community north of Boston of about 100,000 people recently where the columnist, who is an MD, extolled the virtues of CBD products in almost miracle drug proportion.  I immediately thought to myself about how people are being educated so they can make info…

The Opioid Crisis Is Turning Into A Cocaine Crisis

Deaths from cocaine, after holding steady for many years, increased an alarming 52% between 2015 and 2016, according to the CDC, with the trend continuing in the most recent federal data. The stimulant is now killing approximately 13,000 people a year, on track to rival painkiller pills and heroin. …

Psychemedics School Newsletter – April 2018

The post Psychemedics School Newsletter – April 2018 appeared first on Psychemedics.

Psychemedics Frequently Asked Questions

  • When was Psychemedics founded?

    Psychemedics was founded in 1985.

  • Who are Psychemedics key executives?

    Psychemedics's key executives are Raymond C. Kubacki, Neil Lerner and Michael I. Schaffer.

  • How many employees does Psychemedics have?

    Psychemedics has 250 employees.

  • What is Psychemedics revenue?

    Latest Psychemedics annual revenue is $42.7 m.

  • What is Psychemedics revenue per employee?

    Latest Psychemedics revenue per employee is $170.7 k.

  • Who are Psychemedics competitors?

    Competitors of Psychemedics include CareDx, Biological Dynamics and Intelligent Fingerprinting.

  • Where is Psychemedics headquarters?

    Psychemedics headquarters is located at 125 Nagog Park #200, Acton.

  • Where are Psychemedics offices?

    Psychemedics has an office in Acton.

  • How many offices does Psychemedics have?

    Psychemedics has 1 office.